Clinical Study
Triptorelin in the Relief of Lower Urinary Tract Symptoms in Advanced Prostate Cancer Patients: The RESULT Study
Table 1
Baseline characteristics of the study population.
| | Total ( = 325) |
| Indication to start triptorelin treatment at baseline | | Neoadjuvant before radical prostatectomy | 5 (1.5%) | Neoadjuvant before radiotherapy or brachytherapy | 62 (19.1%) | Adjuvant after radical prostatectomy | 12 (3.7%) | Adjuvant after radiotherapy or brachytherapy | 4 (1.2%) | Rising PSA after radical prostatectomy | 29 (8.9%) | Rising PSA after radiotherapy or brachytherapy | 23 (7.1%) | Locally advanced, first line therapy | 135 (41.5%) | Locally advanced, after antiandrogen therapy | 7 (2.2%) | Metastatic, first line therapy | 43 (13.2%) | Other | 17 (5.2%) | Missing data | 0 | Age at first prostate cancer diagnosis (years) | | Mean (SD) | 72.86 (8.26) | TNM staging: T | | T1 | 10 (3.1%) | T1 | 1 (0.3%) | T1a | 1 (0.3%) | T1b | 3 (0.9%) | T1c | 5 (1.6%) | T2 | 47 (14.7%) | T2 | 26 (8.1%) | T2a | 7 (2.2%) | T2b | 9 (2.8%) | T2c | 5 (1.6%) | T3 | 241 (75.1%) | T3 | 182 (56.7%) | T3a | 43 (13.4%) | T3b | 16 (5.0%) | T4 | 22 (6.9%) | T | 1 (0.3%) | Missing data | 4 | TNM staging: N | | N0 | 178 (57.1%) | N1 | 43 (13.8%) | N | 91 (29.2%) | Missing data | 13 | TNM staging: M | | M0 | 199 (63.4%) | M1 | 35 (11.1%) | M1 | 28 (8.9%) | M1a | 1 (0.3%) | M1b | 6 (1.9%) | M | 80 (25.5%) | Missing data | 11 | Gleason score | | ≤6 | 106 (35.5%) | 7 | 99 (33.1%) | ≥8 | 94 (31.4%) | Missing data | 26 |
|
|